Leap therapeutics ipo Results

You are searching for Leap therapeutics ipo, Below listing suggest some keywords related this keyword and listing websites with same content

Find Top Domain Names With

Searches related

Top Keywords Suggestions

1 Leap therapeutics ipo

Most Searched Keywords

Domains Actived Recently

   » Trenchless-works.com (1 seconds ago)

   » Hbms.com (1 seconds ago)

   » Amsaustralia.com (21 seconds ago)

   » Lolclife.com (0 seconds ago)

   » Cargo-nepal.com (6 seconds ago)

   » Bikeshopwarehouse.com (7 seconds ago)

   » Gopherperformance.com (2 seconds ago)

   » Techcodex.com (7 seconds ago)

   » Haugimp.com (41 seconds ago)

   » Hi-luxoptics.com (1 seconds ago)

Extract All Emails from Any Domain

Find All Domains on Any IP/ Domain

About 45 Websites Link


Leap Therapeutics Announces Closing Of Public Offering Of

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 64

C AMBRIDGE, Mass., June 22, 2020/ PRNewswire/-- Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a

Leap Therapeutics Announces Proposed Public Offering Of

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 65

--Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it …

SEC Filing Leap Therapeutics, Inc.

Investors.leaptx.com   DA: 20 PA: 15 MOZ Rank: 37

  • In August 2014, Macrocure completed its initial public offering, and its ordinary shares began trading on The NASDAQ Global Market under the symbol "MCUR." Following the merger, Macrocure's ordinary shares will be delisted from The NASDAQ Global Market
  • 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 617-714-0360

Leap Therapeutics Announces Proposed Public Offering Of

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 71

  • Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is …

Leap Therapeutics Announces Pricing Of $11.5 Million

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 72

  • Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants
  • 1, 2019 /PRNewswire/ -- Leap Therapeutics

Macrocure (MCUR) Stock Soars On Leap Therapeutics Deal

Thestreet.com   DA: 17 PA: 50 MOZ Rank: 72

  • Macrocure (MCUR) signed a definitive merger agreement with Leap Therapeutics on Monday
  • Log In Receive full access to our market insights, commentary, newsletters, breaking news …

Leap Therapeutics, Inc. (LPTX) Stock Price, News, Quote

Finance.yahoo.com   DA: 17 PA: 12 MOZ Rank: 35

  • (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the

Leap Therapeutics Announces Pricing Of $45 Million Of

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 75

  • Leap Therapeutics Announces Pricing of $45 Million of Common Stock and Pre-Funded Warrants
  • CAMBRIDGE, Mass., June 18, 2020 /PRNewswire/ -- Leap Therapeutics, Inc
  • (NASDAQ: LPTX ), a biotechnology

Looking Back In On Leap Therapeutics (NASDAQ:LPTX

Seekingalpha.com   DA: 16 PA: 50 MOZ Rank: 74

  • is a Cambridge, Massachusetts based biotech focused on the development of targeted remedies for various forms of cancer

Leap Therapeutics Initiates Trial, And Other News: The

Seekingalpha.com   DA: 16 PA: 50 MOZ Rank: 75

  • announced the dosing of first patient for its Phase 2a clinical trial DisTinGuish study
  • The trial seeks to assess DKN-01 in combination with tislelizumab, with or without

LPTX Stock Price Leap Therapeutics Inc. Stock Quote (U.S

Marketwatch.com   DA: 19 PA: 21 MOZ Rank: 50

  • Leap Therapeutics stock price target cut to $8 from $13 at Raymond James

Down 19.5% In 4 Weeks, Here's Why You Should You Buy The

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 75

  • (LPTX) has been beaten down lately with too much selling pressure
  • While the stock has lost 19.5% over the past four weeks, there is …

Leap Therapeutics, Inc. Common Stock (LPTX) Short Interest

Nasdaq.com   DA: 14 PA: 43 MOZ Rank: 69

  • Leap Therapeutics, Inc. Common Stock (LPTX) Nasdaq Listed
  • Data is currently not available
  • -0.03 (-1.94%) DATA AS OF Jul 12, 2021

Revisiting Leap Therapeutics (NASDAQ:LPTX) Seeking Alpha

Seekingalpha.com   DA: 16 PA: 45 MOZ Rank: 74

  • focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha

LPTX Leap Therapeutics Inc. Annual Income Statement

Marketwatch.com   DA: 19 PA: 32 MOZ Rank: 65

  • Annual stock financials by MarketWatch
  • View the latest LPTX financial statements, income statements and financial ratios

Leap Therapeutics To Present At Upcoming Virtual Investor

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 82

  • Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Leap Therapeutics Announces Closing Of Previously

Investors.leaptx.com   DA: 20 PA: 50 MOZ Rank: 86

  • 7, 2020 /PRNewswire/ -- Leap Therapeutics, Inc
  • (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of its previously announced equity financing to issue 1,421,801 shares of newly designated Series A mandatorily convertible preferred stock to a lead institutional investor, at a …

News Releases Leap Therapeutics, Inc.

Investors.leaptx.com   DA: 20 PA: 27 MOZ Rank: 64

  • Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
  • Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference
  • Leap Therapeutics Reports First Quarter 2021 Financial Results

Long-Term Equity Anticipation Securities (LEAPS) Definition

Investopedia.com   DA: 20 PA: 18 MOZ Rank: 56

  • Long-term equity anticipation securities (LEAPS) are publicly traded options contracts with expiration dates that are longer than one year, and typically up to three years from issue

Leap Therapeutics (LPTX) Stock Price, Quote & News Stock

Stockanalysis.com   DA: 17 PA: 13 MOZ Rank: 49

  • Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer
  • Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer.

Leap Therapeutics Inc (LPTX) CEO, President, Chairman

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 87

  • CEO, President, Chairman of Leap Therapeutics Inc Christopher Mirabelli bought 571,428 shares of LPTX on 02/05/2019 at an average price of $1.75 a share
  • The total cost of this purchase was $999,999.

Leap Therapeutics LPTX License Agreement And Offering +53%

Biopharmcatalyst.com   DA: 24 PA: 50 MOZ Rank: 95

  • (Nasdaq: LPTX) shares closed up 53% to $1.61 following its announcement it will receive an upfront payment of $3m following a license agreement with BeiGene, Ltd
  • (Nasdaq: BGNE) for the development of its pipeline candidate DKN-01, in Asia (excluding Japan), Australia, and New Zealand.

Management Page Leap Therapeutics

Leaptx.com   DA: 14 PA: 16 MOZ Rank: 52

  • Doug Onsi has served as Leap’s Chief Financial Officer, Treasurer and Secretary since 2011 and became the President & CEO in April of 2020
  • He has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc
  • which was sold to Roche Holdings, Inc.

Repare Soars To Largest Ever IPO Of A Canadian Biotech

Theglobeandmail.com   DA: 23 PA: 50 MOZ Rank: 96

  • Montreal cancer drug developer Repare Therapeutics Inc
  • joined the ranks of US$1-billion Canadian drug developers Friday, debuting in late-morning trading at $32.05 a …

Leap Therapeutics Reports First Quarter 2021 Financial

Marketwatch.com   DA: 19 PA: 50 MOZ Rank: 93

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Leap Therapeutics Announces FDA Fast Track Designation

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 92

  • (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S
  • Food and Drug Administration (FDA) has

Leap Therapeutics : Completes Enrollment In Gastric

Marketscreener.com   DA: 22 PA: 50 MOZ Rank: 98

Leap Therapeutics : Completes Enrollment in Gastric, Gastroesophageal Junction Cancer Combo Therapy Trial

How To Buy Leap Therapeutics Stock

Finder.com   DA: 14 PA: 28 MOZ Rank: 69

In this case Leap Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Leap Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0383% of the tradable shares (for every 100,000 tradable Leap Therapeutics shares, roughly 38 shares are currently held short).

Leap Therapeutics To Present At H.C. Wainwright BioConnect

Finance.yahoo.com   DA: 17 PA: 50 MOZ Rank: 95

  • (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E
  • Onsi, President and Chief Executive

The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And

Benzinga.com   DA: 16 PA: 50 MOZ Rank: 95

  • Leap Therapeutics Inc La Jolla, California-based Avidity Biosciences, Inc
  • priced its upsized IPO of 14.4 million shares at $18 per share compared to …

LPTX Leap Therapeutics Inc. Profile MarketWatch

Marketwatch.com   DA: 19 PA: 37 MOZ Rank: 86

  • is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer
  • Its clinical stage programs are DKN-01

Leap Therapeutics To Present At Ladenburg Thalmann 2021

Streetinsider.com   DA: 21 PA: 50 MOZ Rank: 19

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Leap Therapeutics To Present At Raymond James 2021 Virtual

Streetinsider.com   DA: 21 PA: 50 MOZ Rank: 18

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

IShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB

Benzinga.com   DA: 16 PA: 50 MOZ Rank: 99

  • Bethesda, Maryland-based Gain Therapeutics, Inc
  • is proposing to offer 3.64 million shares of its common stock in an initial public offering, with the

Caribou Raises $304M In One Of Gene Editing's Most

Biopharmadive.com   DA: 21 PA: 45 MOZ Rank: 100

Dive Brief: Caribou Biosciences, one of the first biotech companies formed to turn CRISPR gene editing technology into medicines for humans, raised just over $300 million in an initial public offering priced Thursday, making the leap to public markets roughly 10 years after its founding.; The IPO, which follows four months after Caribou's venture backers invested another $115 million in the

Leap Therapeutics, Inc. (LPTX) Reports Q1 Loss, Lags

Nasdaq.com   DA: 14 PA: 50 MOZ Rank: 99

  • (LPTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11

Pear Therapeutics Takes The Public Leap In A $1.6B SPAC

Emarketer.com   DA: 17 PA: 50 MOZ Rank: 14

  • The news: Digital therapeutics (DTx) firm Pear Therapeutics revealed it’s going public in a SPAC deal with Thimble Point Acquisition Corp at an estimated value of $1.6 billion
  • It expects to have $400 million in net cash once the deal closes
  • How we got here: Pear’s news arrives after its $100 million Series D funding in March—cash it said it would use to get its substance abuse, opioid

For Patients Leap Therapeutics

Leaptx.com   DA: 14 PA: 13 MOZ Rank: 64

  • Leap Therapeutics is committed to developing drugs to change the practice of cancer medicine
  • Our first priority in this commitment is to bring forward promising cancer drugs through our clinical trials
  • Leap Therapeutics development resources are focused on conducting Good Clinical Practice clinical trials and obtaining regulatory approval of

Leap Therapeutics Reports First Quarter 2021 Financial Results

Streetinsider.com   DA: 21 PA: 50 MOZ Rank: 12

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Leap Therapeutics To Present At Raymond James 2021 Virtual

Newsfilter.io   DA: 13 PA: 50 MOZ Rank: 11

  • Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference
  • Published: Jun 14, 2021, 11:00 AM UTC PR Newswire CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc
  • (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E

IShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB

Benzinga.com   DA: 16 PA: 50 MOZ Rank: 10

  • (NASDAQ: LPTX): Additional data from the Phase 2 study of DKN-01 and Paclitaxel chemotherapy medication in endometrial cancer
  • Celsion Corporation (NASDAQ: CLSN) IPOs

Recently Analyzed Sites

Trenchless-works.com (1 seconds ago)

Hbms.com (1 seconds ago)

Amsaustralia.com (21 seconds ago)

Lolclife.com (0 seconds ago)

Cargo-nepal.com (6 seconds ago)

Bikeshopwarehouse.com (7 seconds ago)

Gopherperformance.com (2 seconds ago)

Techcodex.com (7 seconds ago)

Haugimp.com (41 seconds ago)

Hi-luxoptics.com (1 seconds ago)

Mahoneswallpapershop.com (32 seconds ago)

Sspeterandpaulplains.com (6 seconds ago)

Volamtrungnguyen.net (2 seconds ago)

Beyondavatars.com (0 seconds ago)

Unblocked.vet (0 seconds ago)

Amsco-ac.com (6 seconds ago)

Goodshepherdpca.net (4 seconds ago)